Related Experiment Video
Updated: Jun 25, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet agents for prevention of recurrent ischemic stroke
1Falls Community Health, Sioux Falls, USA.
Insights
Preventing a second stroke is crucial. Aspirin plus extended-release dipyridamole (ASA-ERDP) may be more effective than aspirin alone for secondary stroke prevention, with clopidogrel showing similar efficacy to ASA-ERDP.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Secondary stroke prevention is a key goal for patients with ischemic stroke or TIA.
- Common antiplatelet therapies include aspirin, clopidogrel, and ASA-ERDP.
Purpose of the Study:
- To review the comparative efficacy of different antiplatelet regimens for secondary stroke prevention.
- To discuss the role of individual patient factors in guiding antiplatelet therapy selection.
Main Methods:
- Literature review of studies comparing aspirin, clopidogrel, and ASA-ERDP for secondary stroke prevention.
- Analysis of findings from the PROFESS trial.
Main Results:
- ASA-ERDP appears more effective than aspirin monotherapy.
- Clopidogrel may be more effective than aspirin.
- ASA-ERDP and clopidogrel demonstrated equal effectiveness in the PROFESS trial for reducing recurrent stroke risk.
Conclusions:
- While guidelines exist, individualized patient factors like cost, tolerability, adherence, and comorbidities are critical for selecting antiplatelet therapy.
- Further research is needed to directly compare the efficacy and safety of ASA-ERDP and clopidogrel.
Abstract:
Prevention of secondary stroke is an important objective in the management of patients with ischemic stroke or TIA. Commonly used antiplatelet regimens for this indication include aspirin, clopidogrel and ASA-ERDP. Based on current evidence, ASA-ERDP appears to be more effective than aspirin monotherapy, and one study has shown that clopidogrel may be more effective than aspirin. Furthermore, results from the recent PROFESS trial suggest that ASA-ERDP and clopidogrel are equally effective in reducing the risk of recurrent stroke, though further studies are needed to compare the efficacy and safety of these two agents. Recently updated guidelines have attempted to define the appropriate use of antiplatelet therapy for the prevention of recurrent stroke. However, individual patient characteristics need to be considered when selecting therapy. Specifically, factors such as cost, tolerability, adherence and other comorbidities may guide treatment choices.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coronary Artery Disease V: Interprofessional Care
